Clinical Trials Directory

Trials / Unknown

UnknownNCT05790083

Skin Efficacy and Tolerability of a Cosmetic Product Combination Over 3 Months in Subjects With Atopic Eczema

Assessment of the Short- and Long-Term Skin Efficacy and Tolerability of a Cosmetic Product Combination of Body Lotion and Intensive Care Over 3 Months in Subjects With Atopic Eczema

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
100 (actual)
Sponsor
Bionorica SE · Industry
Sex
All
Age
2 Years – 75 Years
Healthy volunteers
Accepted

Summary

The aim of this exploratory study is to investigate the short- and long-term efficacy and tolerability of a cosmetic product combination consisting of a body lotion and an intensive care product in subjects with atopic eczema over 3 months of use. Efficacy is assessed by instrumental measurements of skin condition (sub-panel), clinical examinations, and questionnaires.

Detailed description

The objective of this exploratory study is to investigate the short- and long-term efficacy and tolerability of a cosmetic product combination consisting of a body lotion and an intensive care product in subjects with atopic eczema over 3 months of use. For efficacy and tolerability evaluation, an objective dermatological assessment will be performed, in addition to assessing efficacy, the severity of atopic eczema will be assessed using the validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD). Further, the effect of the test product combination on symptom severity, disease control (recap of atopic eczema (RECAP)), quality of life and well-being will be evaluated by the subjects or the subjects' parents/ legal guardians. The subjects or the subjects' parents/ legal guardians will also document the frequency of flare-ups, required physician visits and the use of cortisone administration as well as their/ their child's well-being in a diary. Additionally, the influence of the test product combination on the skin barrier will be assessed in a sub-panel with dry legs by measuring the transepidermal water loss by Aquaflux and by sampling of biological material for analysis of skin lipids and corneocyte maturity before and after 3 months of product use.

Conditions

Interventions

TypeNameDescription
OTHERBody Lotion and Intensive CareBody Lotion, applied twice daily on whole body, for 3 months. Intensive Care, applied as needed on affected body areas.

Timeline

Start date
2023-01-03
Primary completion
2023-03-30
Completion
2023-03-30
First posted
2023-03-29
Last updated
2023-03-29

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT05790083. Inclusion in this directory is not an endorsement.